ESMO 2014: Precision Medicine Sessions

Why precision medicine in cancer care? Because each patient’s cancer is unique and may respond differently to the standard treatment approach.

The theme for ESMO 2014: ‘Precision Medicine in Cancer Care’ was chosen to drive dynamic discussions and knowledge exchange in an environment of world-class experts dedicated to improving research, patient treatment and outcome. Here, we highlight sessions which look at this subject in more detail.

CNS tumours

Special Symposium: Current concepts and future avenues in meningioma

Objectives: Understanding the challenges and morbidity of this non-malignant disease • Biological insight to pave the way to novel and targeted treatments • Indications and limitations of the current standard of care of the various meningioma subtypes

  • Sunday 28 September 2014, 14:15-15:45
  • Chair: J.Tonn – Munich/DE, Co-Chair: M.Preusser – Vienna/AT

Developmental therapeutics

Special Symposium: Molecular profiling – challenges and perspectives

Objectives: From a viewpoint of drug development in general, this session should represent the missing link between the basic science/translational research sessions and the still organ-oriented sessions • To what extent precision medicine based on molecular profiling has reached the clinical reality of today • Potential problems faced when integrating precision medicine into oncologic management

  • Sunday 28 September 2014, 09:00-10:30
  • Chair: C. Dittrich – Vienna/AT, Co-Chair: J.C. Soria  - Villejuif/FR

Gastrointestinal tumours

Special Symposium: Advances in precision medicine of metastatic colorectal cancer

Objectives: Insight into the future molecular understanding of mCRC, leading to a (potential) new classification and the consecutive development of therapeutics • New classes of anticancer treatments in this disease, e.g. immunotherapy

  • Sunday 28 September 2014, 14:15-15:45
  • Chair: W. Steward – Leicester/UK, Co-Chair: T. Seufferlein – Ulm/DE

Special Symposium: Towards personalised medicine in gastric, pancreatic and liver cancer – from “omics” research to treatment

Objectives: To offer attendees the possibility to get a clear picture of how new developments in “omics” may potentially translate into clinical actions for patients with gastric, pancreatic and liver cancers

  • Monday 29 September 2014, 16:00-17:30
  • Chair: E. Martinelli – Napoli/IT, Co-Chair: M. Ducreux – Villejuif/FR

Genitourinary tumours

Patient cases: Multimodal treatment approaches in bladder cancer

  • Saturday 27 September 2014, 08:00-09:00
  • Co-Chairs: T.Lebret – Suresnes/FR, N.James – Birmingham/UK, D.Solit – New York, NY/US

Special Symposium: Precision medicine in prostate cancer

Objectives: To provide Insight in prostate cancer biology and heterogeneity, provide rationale and link current therapy/drug development to the impetus for disease biology • Inform on biomarker development and on current precision medicine perspectives specific to prostate cancer

  • Saturday 27 September 2014, 14:00-15:50
  • Chair: M. Rubin – New York/US, Co-Chair: E. Efstathiou – Houston/US

Special Symposium: Beyond tumour heterogeneity – new pathways in kidney cancer

Objectives: To present the latest molecular classification of kidney cancer and discuss relevance for practising clinicians • Highlight major clinical problems such as drug resistance and lack of predictive biomarkers for drug therapies • Focus on new targets and drugs, particularly immunotherapies such as anti-PD1 agents

  • Monday 29 September 2014, 09:15-10.45
  • Chair: V.Grunwald – Hannover/DE, Co-Chair: C.N. Sternberg – Roma/IT

Head & Neck Cancer

Objectives: To discuss therapeutic perspectives for squamous cell carcinoma, including immunotherapy, according to novel targets and better individual patient selection • Identify therapeutic targets for salivary gland cancers, still orphan diseases • Integrate innovative technology for next generation trials based on biological tumour characteristics

Special Symposium: Personalised medicine in head and neck cancer

  • Saturday 27 September 2014, 11:00-12:30
  • Chair: S.Faivre – Clichy/FR, Co-Chair: J.J Grau – Barcelona/ES

Immunotherapy

Keynote Lecture: Delivering precision immunotherapy

  • Saturday 27 September 2014, 13:00-13:45
  • Chair: Chair: G.Coukos – Lausanne/CH

Public Health and Economics

Special Symposium: The impact on health services from personalised targeted therapies

Objectives: The budgetary impact of the cost of new diagnostic procedures and therapies and the changes in health services associated with them • Integration of all aspects of cancer care – ranging from health promotion to rehabilitation, reintegration and palliation

  • Monday 29 September 2014, 14:15-15:45
  • Chair: J.Borras – Barcelona/ES, Co-Chair: T.Albreht – Ljubljana/SI

Supportive and Palliative Care

Special Symposium: Targeting precision medicine toxicity

Objectives: to learn about the completely different side effects from all the new therapies available over the past years

  • Saturday 27 September 2014, 15:55-17:30
  • Chair:  M.Dicato – Luxembourg/LU, Co-Chair: F.Roila – Terni/IT